Vistin Pharma ASA

Vistin Pharma maintains a strong liquidity position, with a current ratio of 2.58 and a liquidity risk score of low. The company's cash and equivalents amount to NOK 16.4 million, and it has a free cash flow of NOK 25.2 million, indicating a solid ability to fund operations and invest in growth. The company is debt-free, with a debt-to-equity ratio of 0.0, which further supports its financial stability. In terms of profitability, Vistin Pharma's return on equity (ROE) of 22.73% and return on assets (ROA) of 17.01% are well above the industry median for pharmaceutical companies. The company's gross margin of 66.5% (calculated from gross profit of NOK 300.8 million on revenue of NOK 452.3 million) is also strong, suggesting efficient cost management and pricing power. The operating margin of 20.4% (NOK 92.4 million on revenue of NOK 452.3 million) further supports the company's profitability. Vistin Pharma's revenue is concentrated in a single business segment, as disclosed in its latest financial report. The company does not provide geographic revenue breakdowns, but it is primarily focused on the European market. The lack of geographic diversification may expose the company to regional economic or regulatory risks. The company's revenue growth has been robust, with a reported revenue of NOK 452.3 million in the latest period, compared to NOK 198.99 million in the previous period. This represents a year-over-year increase of approximately 127%. The outlook for the current fiscal year is positive, with expectations of continued growth driven by the expansion of its product portfolio and market penetration. Vistin Pharma's risk profile is favorable, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is stable. The company's shares are not subject to near-term dilution, as the basic and diluted shares outstanding are the same. The company has not made any recent equity issuances or announced plans for future dilution. Recent events include the company's strong revenue performance and the absence of any material adverse events in its latest filings. The company has not disclosed any significant regulatory or legal challenges, and its financial health remains strong. The company's management has not issued any forward-looking statements that suggest near-term operational or financial risks.